Public Company Edition: Alumis grosses $250m after it planned to raise up to $317.7m in its IPO. Also, Zealand adds $1bn in a post-data offering, Tectonic and Eliem close $130.7m and $120m private placements to support recent mergers, and Ginkgo cuts 35% of its workforce.

Deal Snapshot: Ginkgo will earn up to $406m in fees plus royalties as it works with Boehringer Ingelheim to mine its metagenomics database for drug candidates.

Public Company Edition: MAIA launches a $10m initial public offering, the first in the US since May, but NewAmsterdam opts for the SPAC route to the stock market. Also, Legend raises $350m in a follow-on offering, Iveric obtains access to $250m in debt and Otonomy cuts costs after a Phase II failure.

Troubled Zymergen will continue its ongoing restructuring efforts and Ginkgo, which has seen its own challenges since going public, will use Zymergen’s automation expertise to accelerate its growth.